Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

Condition:   Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion Intervention:   Drug: larotrectinib(Vitrakvi, BAY2757556) Sponsor:   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials